The microbiome and psoriatic arthritis topical collection on psoriatic arthritis

Current Rheumatology Reports

Volumn 16, Issue 3, 2014, Pages

  Eppinga, Hester ^a   Konstantinov, Sergey R ^a   Peppelenbosch, Maikel P ^a   Thio, H Bing ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmunity; Microbiome; Microbiota; Mycobiome; Psoriasis; Psoriatic arthritis; Spondyloarthritis

Indexed keywords

ANTIBIOTIC AGENT; EDIBLE OIL; PREBIOTIC AGENT; PROBIOTIC AGENT; SEAL OIL; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BIOLOGICAL THERAPY; CELLULAR IMMUNITY; COMMENSAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSBIOSIS; ENVIRONMENTAL FACTOR; FECAL MICROBIOTA TRANSPLANTATION; FUNGAL COMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; MUCOSAL IMMUNITY; PATHOGENESIS; PSORIASIS; PSORIATIC ARTHRITIS; SKIN FLORA; AUTOIMMUNITY; FECES; FUNGUS; IMMUNOLOGY; INTESTINE; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGY; MICROFLORA; REVIEW; SKIN; SYMBIOSIS; T LYMPHOCYTE SUBPOPULATION; TISSUE TRANSPLANTATION;

ANTI-BACTERIAL AGENTS; ARTHRITIS, PSORIATIC; AUTOIMMUNITY; FECES; FUNGI; HUMANS; INTESTINES; MICROBIOTA; PROBIOTICS; SKIN; SYMBIOSIS; T-LYMPHOCYTE SUBSETS; TISSUE TRANSPLANTATION;

EID: 84894625467     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0407-2     Document Type: Article

References (84)

1. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36(2):361-7.
2. Christophers E, Barker JN, Griffiths CE, Dauden E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548-54.
3. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol. 2005;17(4):406-12. (Pubitemid 41058399)
4. Konstantinov SR, van der Woude CJ, Peppelenbosch MP. Do pregnancy-related changes in the microbiome stimulate innate immunity? Trends Mol Med. 2013;19(8):454-9.
5. Ottman N, Smidt H, de Vos WM, Belzer C. The function of our microbiota: who is out there and what do they do? Front Cell Infect Microbiol. 2012;2:104.
6. Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012;9(10):577-89.
7. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17(3):323-33.
8. Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti-Infect Ther. 2010;8(4):435-54.
9. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262-7.
10. Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep. 2013;15(3):314. 012-0314-y.
11. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174-80.
12. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol. 2012;30:759-95.
13. de Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev. 2012;70 Suppl 1:S45-56.
14. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011;60(5):631-7.
15. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103.
16. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-85.
17. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575-84.
18. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-6.
19. Kempsell KE, Cox CJ, Hurle M, Wong A, Wilkie S, Zanders ED, et al. Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue. Infect Immun. 2000;68(10):6012-26.
20. Stebbings S, Jenks K, Roberts R, Schultz M. The immune response to gut bacteria in spondyloarthritis: a role in pathogenesis? JCRMM. 2010;1:1-10.
21. Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012;336(6086):1314-7.
22. Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog. 2010;6(1):e1000713.
23. Iliev ID, Underhill DM. Striking a balance: fungal commensalism versus pathogenesis. Curr Opin Microbiol. 2013;16(3):366-73.
24. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65-8.
25. Ott SJ, Kuhbacher T, Musfeldt M, Rosenstiel P, Hellmig S, Rehman A, et al. Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol. 2008;43(7):831-41. (Pubitemid 351918525)
26. Mason KL, Erb Downward JR, Falkowski NR, Young VB, Kao JY, Huffnagle GB. Interplay between the gastric bacterial microbiota and Candida albicans during postantibiotic recolonization and gastritis. Infect Immun. 2012;80(1):150-8.
27. Naglik JR, Fidel Jr PL, Odds FC. Animal models of mucosal Candida infection. FEMS Microbiol Lett. 2008;283(2):129-39. (Pubitemid 351678571)
28. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913-8. (Pubitemid 24177098)
29. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996;64(12):5225-32. (Pubitemid 26403985)
30. Martins FS, Dalmasso G, Arantes RM, Doye A, Lemichez E, Lagadec P, et al. Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS One. 2010;5(1):e8925.
31. Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G1083-92.
32. Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host Microbe. 2012;12(4):496-508.
33. Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol. 2012;10(10):717-25.
34. Fung I, Garrett JP, Shahane A, Kwan M. Do bugs control our fate? The influence of the microbiome on autoimmunity. Curr Allergy Asthma Rep. 2012;12(6):511-9.
35. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268-73.
36. Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev. 2013;12(5):599-606.
37. Curran SA, FitzGerald OM, Costello PJ, Selby JM, Kane DJ, Bresnihan B, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol. 2004;172(3):1935-44. (Pubitemid 38116844)
38. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001;166(4):2878-86. (Pubitemid 32173531)
39. Choy E. T cells in psoriatic arthritis. Curr Rheumatol Rep. 2007;9(6):437-41. (Pubitemid 350305199)
40. Hormannsperger G, Clavel T, Haller D. Gut matters: microbe-host interactions in allergic diseases. J Allergy Clin Immunol. 2012;129(6):1452-9. The authors established the importance of microbe-host interaction in the development of immune-mediated disorders.
41. Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815-27.
42. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149(7):1578-93.
43. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008;38(10):2636-49.
44. Krueger JG. Hiding under the skin: A welcome surprise in psoriasis. Nat Med. 2012;18(12):1750-1.
45. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1-2):419-29.
46. Benham H, Norris P, Goodall J, Wechalekar MD, Fitzgerald O, Szentpetery A, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15(5):R136.
47. Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:12-29.
48. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211-6.
49. Ding HS, Yang J, Yang J, Ding JW, Chen P, Zhu P. Interleukin-17 contributes to cardiovascular diseases. Mol Biol Rep. 2012;39(7):7473-8.
50. Ritchlin CT. From skin to bone: translational perspectives on psoriatic disease. J Rheumatol. 2008;35(7):1434-7. (Pubitemid 352000800)
51. Yamamoto T. Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol. 2011;21(5):660-6.
52. Gladman DD. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol. 1994;8(2):379-94. (Pubitemid 24189845)
53. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314-21.
54. Hsieh J, Kadavath S, Efthimiou P. Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin Rheumatol 2013 Nov 19
55. Fry L, Baker BS, Powles AV, Fahlen A, Engstrand L. Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol 2013 Mar 23
56. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;3(7):e2719.
57. Castelino M, Eyre S, Upton M, Ho P, Barton A. The bacterial skin microbiome in psoriatic arthritis, an unexplored link in pathogenesis: challenges and opportunities offered by recent technological advances. Rheumatology (Oxford) 2013 Sep 24. First article describing the hypothetical relationship of specifically psoriatic arthritis with the (skin) microbiome.
58. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al. Compartmentalized control of skin immunity by resident commensals. Science. 2012;337(6098):1115-9.
59. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180(6):2359-64. (Pubitemid 24351619)
60. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):R569-80.
61. Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol 2013 Nov 17
62. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20(3):451-71. (Pubitemid 43843072)
63. Lindqvist U, Kristjansson G, Pihl-Lundin I, Hagforsen E, Michaelsson G. Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris. J Rheumatol. 2006;33(5):924-7.
64. Scarpa R, Manguso F, D'Arienzo A, D'Armiento FP, Astarita C, Mazzacca G, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27(5):1241-6. (Pubitemid 30262511)
65. Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011;13(5):409-15.
66. Schatteman L, Mielants H, Veys EM, Cuvelier C, De Vos M, Gyselbrecht L, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol. 1995;22(4):680-3.
67. Mielants H, De Keyser F, Baeten D, Van den Bosch F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep. 2005;7(3):188-94.
68. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529-34. (Pubitemid 350087599)
69. Binus AM, Han J, Qamar AA, Mody EA, Holt EW, Qureshi AA. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2012;26(5):644-50.
70. Arck P, Handjiski B, Hagen E, Pincus M, Bruenahl C, Bienenstock J, et al. Is there a 'gut-brain-skin axis'? Exp Dermatol. 2010;19(5):401-5.
71. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013;72(7):1200-5.
72. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42(11):2325-9. (Pubitemid 30333412)
73. Braun J. Therapy of spondyloarthritides. Adv Exp Med Biol. 2009;649:133-47.
74. Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R, Busscher HJ. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 2011;9(1):27-38.
75. Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science. 2012;336(6086):1255-62.
76. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2011;106(12):2133-42.
77. Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease-a nationwide, register-based finnish case-control study. Am J Epidemiol. 2012;175(8):775-84.
78. Ceapa C, Wopereis H, Rezaiki L, Kleerebezem M, Knol J, Oozeer R. Influence of fermented milk products, prebiotics and probiotics on microbiota composition and health. Best Pract Res Clin Gastroenterol. 2013;27(1):139-55.
79. Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin N Am. 2011;40(1):207-22.
80. Hormannsperger G, von Schillde MA, Haller D. Lactocepin as a protective microbial structure in the context of IBD. Gut Microbes. 2013;4(2):152-7.
81. Madland TM, Bjorkkjaer T, Brunborg LA, Froyland L, Berstad A, Brun JG. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. J Rheumatol. 2006;33(2):307-10. (Pubitemid 43209307)
82. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15.
83. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107(10):1452-9.
84. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913-6. e7.